Stay updated with breaking news from Ryan Eckmeier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced a milestone-based Other Transaction Agreement (OTA) with the United States Department of...
/PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced a milestone-based Other Transaction Agreement (OTA) with the United States Department of...
California-based Dynavax Technologies Corporation and the U.S. Department of Defense (DOD) today announced an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018®.
Dynavax will conduct a Phase 2 clinical trial combining the US Department of Defense’ rF1V vaccine with its CpG 1018 adjuvant.